The Business Research Company’s report on the Pet Cancer Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the pet cancer therapeutics market’s growth in recent years?
Increased pet healthcare expenditure is expected to propel the growth of the pet cancer therapeutics market going forward. Pet healthcare expenditure refers to the amount of money spent on veterinary services, medicines, and other healthcare-related expenses for pets. The increasing expenditure on pet healthcare reflects the growing trend of pet owners’ willingness to invest in the well-being of their pets, which can translate to increased demand for pet cancer therapeutics. For instance, according to the 2023 State of the Industry Report, published by the North American Pet Health Insurance Association (NAPHIA), a US-based pet health insurance organizations association, the total number of pets insured in the United States at year-end 2022 was 4.8 million, a 22% increase since 2021. Therefore, increased pet healthcare expenditure is driving the pet cancer therapeutics market.
Access Your Free Sample of the Global Pet Cancer Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9984&type=smp
How does the future projection of the pet cancer therapeutics market size compare to its historical growth?
The pet cancer therapeutics market size has grown rapidly in recent years. It will grow from $0.39 billion in 2024 to $0.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rise in pet ownership, advancements in veterinary medicine, increased awareness of pet health, humanization of pets, expansion of veterinary services.
The pet cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to growing aging pet population, advancements in cancer treatment, rising veterinary oncology services, pet insurance and healthcare plans, global expansion of pet care services. Major trends in the forecast period include rise in nutraceuticals and integrative therapies, increased availability of targeted diagnostic tests, collaboration between veterinary and human oncology, introduction of novel chemotherapeutic agents, growing awareness and pet owner education.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=9984&type=smp
Which key players are shaping the future of the pet cancer therapeutics market?
Major companies operating in the pet cancer therapeutics market include AB Science, Boehringer Ingelheim GmbH, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., virology and bacteriology, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Dechra Pharmaceuticals plc, Norbrook Laboratories Ltd., AdvaVet Inc., Oasmia Pharmaceuticals AB, Zenoaq Co. Ltd., Morphogenesis Inc., Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc.
What trends will propel the growth and evolution of the pet cancer therapeutics market?
Major companies operating in the pet cancer therapeutics market are developing technologies such as epigenetic technology to enhance treatment efficacy and precision in targeting cancer cells, ultimately improving outcomes for pets affected by cancer. Epigenetic technology refers to methods that modify gene expression without changing the underlying DNA sequence, often influencing cellular behavior and potential therapeutic outcomes. For instance, in April 2024, VolitionRx Limited, a US-based multi-national epigenetics company, launched the Nu.Q Vet Cancer Test. The Nu.Q Vet Cancer Test operates on the Element i+ Analyzer, allowing for quick results—typically within about 6 minutes. It utilizes an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which can indicate the presence of cancer.
Which regions are expected to become dominant players in the pet cancer therapeutics market?
North America was the largest region in the pet cancer therapeutics market in 2024. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/pet-cancer-therapeutics-global-market-report
What are the emerging key segments in the pet cancer therapeutics market, and how are they evolving?
The pet cancer therapeutics market covered in this report is segmented –
1) By Cancer Type: Melanoma, Mast Cell Cancer, Lymphoma, Mammary And Squamous Cell Cancer
2) By Species: Dogs, Cats, Other Species
3) By Therapy: Chemotherapy, Radiation Therapy, Immunotherapy, TomoTherapy, Other Therapies
4) By End User: Veterinary Hospitals, Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, Other End Users
Subsegments:
1) By Melanoma: Surgical Interventions, Chemotherapy, Immunotherapy, Targeted Therapy
2) By Mast Cell Cancer: Surgery, Chemotherapy, Tyrosine Kinase Inhibitors, Radiation Therapy
3) By Lymphoma: Chemotherapy Protocols, Steroid Therapy, Radiation Therapy, Immunotherapy
4) By Mammary And Squamous Cell Cancer: Surgical Treatment, Chemotherapy, Radiation Therapy, Palliative Care Options
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9984
How is the pet cancer therapeutics market defined?
Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. This therapeutics depends on several factors such as the type and stage of cancer, along with the pet’s age and overall health.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
